logo
  

Merck, Eisai Receive Positive CHMP Opinions For Keytruda + Lenvima In Two Different Types Of Cancer

Merck & Co. Inc. (MRK) and Eisai said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has adopted positive opinions recommending approval of the combination of Keytruda, Merck's anti-PD-1 therapy, plus Lenvima, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for two different indications.

One positive opinion is for the first-line treatment of adult patients with advanced renal cell carcinoma, and the other is for the treatment of adult patients with advanced or recurrent endometrial carcinoma (EC) who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and are not candidates for curative surgery or radiation.

Decisions on the CHMP's recommendations will be given by the European Commission for marketing authorization in the EU, and are expected in the fourth quarter of 2021.

LENVIMAis marketed as KISPLYX in the European Union for the treatment of advanced renal cell carcinoma or RCC.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Lily's Sweets is recalling 18,855 cases of 7-ounce Peppermint Flavor Baking Chips citing the presence of undeclared soy lecithin, a known allergen, the U.S. Food and Drug Administration said. The product was a limited holiday seasonal offering available exclusively at Walmart stores in the United States. Cryptocurrency Dogecoin's price jumped over 15% on Friday, but later lost some of the gains, after Tesla Inc. (TSLA) CEO Elon Musk announced that the luxury car maker will start accepting the meme cryptocurrency as payment for its merchandise. "Tesla merch buyable with Dogecoin," Musk tweeted on Friday. Dogecoin... US investment bank JPMorgan Chase & Co. reported Friday a profit for the fourth quarter that declined 14 percent from last year, hurt primarily by higher noninterest expense and lower credit reserve releases. Both adjusted earnings per share and revenues for the quarter topped analysts' expectations.
Follow RTT